Navigation Links
Genentech/Roche/Chugai's Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
Date:10/21/2008

ssion results in resistance to conventional hormonal and targeted therapies, leaving chemotherapy as the only treatment option for patients with triple-negative breast cancer," said Niamh Murphy, Ph.D., analyst at Decision Resources. "As a result, there is a significant unmet need for the development of effective agents for the treatment of triple-negative breast cancer."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Decision Resources Decision Resources, Inc.

Christopher Comfort Elizabeth Marshall

781-296-2597 781-296-2563

ccomfort@dresources.com emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Avastin Added to Chemo Helps Women With Advanced Breast Cancer
2. Avastin Added to Chemo Helps Women With Advanced Cancer
3. Off-Label Avastin Use for Wet Macular Degeneration
4. FDA OKs Avastin for Advanced Breast Cancer
5. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
6. Despite Oncologists Willingness to Prescribe Avastin for Treatment of Breast Cancer, the FDA is Likely to Rule Against the Product on February 23
7. Many More Patients Can Now Benefit from Avastins Proven Survival Benefits
8. Taxol with avastin produces noteworthy results
9. FDA Panel Says No to Avastin for Advanced Breast Cancer
10. Rising Garners Top Honors on the Private Company Indexs Top Five Growth Companies List for Q1 2008
11. Study garners unique mating photos of wild gorillas
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 2Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 3Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 1Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 2Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 3Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 4Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 5Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 6Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 7Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 8Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 9Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 10Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 11Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 12Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 13Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 14Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 15Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 16Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 17Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 18The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston MA Hynes Convention Center October 31 November 3 20 5061 1The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston MA Hynes Convention Center October 31 November 3 20 5061 2American Society of Plastic Surgeons hosts 78th annual meeting 58275 1American Society of Plastic Surgeons hosts 78th annual meeting 58275 2American Society of Plastic Surgeons hosts 78th annual meeting 58275 3